(0.16%) 5 139.50 points
(0.10%) 38 480 points
(0.25%) 17 890 points
(-0.17%) $83.71
(0.94%) $1.941
(0.30%) $2 354.20
(0.56%) $27.69
(1.72%) $938.00
(-0.20%) $0.933
(-0.33%) $10.99
(-0.31%) $0.798
(1.19%) $92.97
3 days till quarter result
(amc 2024-05-02)
Expected move: +/- 2.37%
@ $270.69
发出时间: 27 Apr 2024 @ 03:51
回报率: -0.26%
上一信号: Apr 27 - 01:55
上一信号:
回报率: -0.03 %
Live Chart Being Loaded With Signals
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas...
Stats | |
---|---|
今日成交量 | 2.44M |
平均成交量 | 2.96M |
市值 | 144.69B |
EPS | $0 ( 2024-04-25 ) |
下一个收益日期 | ( $3.76 ) 2024-05-02 |
Last Dividend | $2.25 ( 2024-02-15 ) |
Next Dividend | $0 ( N/A ) |
P/E | 21.60 |
ATR14 | $5.96 (2.21%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-18 | Santos Esteban | Sell | 6 137 | Common Stock |
2024-03-18 | Reese David M | Sell | 6 202 | Common Stock |
2024-03-18 | Miller Derek | Sell | 475 | Common Stock |
2024-03-18 | Khosla Rachna | Sell | 438 | Common Stock |
2024-03-18 | Grygiel Nancy A. | Sell | 703 | Common Stock |
INSIDER POWER |
---|
58.81 |
Last 97 transactions |
Buy: 472 102 | Sell: 97 922 |
音量 相关性
Amgen Inc 相关性 - 货币/商品
Amgen Inc 财务报表
Annual | 2023 |
营收: | $28.19B |
毛利润: | $19.74B (70.02 %) |
EPS: | $12.56 |
FY | 2023 |
营收: | $28.19B |
毛利润: | $19.74B (70.02 %) |
EPS: | $12.56 |
FY | 2022 |
营收: | $26.32B |
毛利润: | $19.92B (75.66 %) |
EPS: | $12.18 |
FY | 2021 |
营收: | $25.98B |
毛利润: | $19.53B (75.16 %) |
EPS: | $10.06 |
Financial Reports:
No articles found.
Amgen Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$1.940 (N/A) |
$1.940 (N/A) |
$2.13 (N/A) |
$2.13 (N/A) |
$2.13 (N/A) |
$2.13 (N/A) |
$2.25 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.280 | 2011-08-16 |
Last Dividend | $2.25 | 2024-02-15 |
Next Dividend | $0 | N/A |
Payout Date | 2024-03-07 | |
Next Payout Date | N/A | |
# dividends | 51 | -- |
Total Paid Out | $61.13 | -- |
Avg. Dividend % Per Year | 2.40% | -- |
Score | 5.46 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.55 | |
Div. Directional Score | 8.29 | -- |
Year | Amount | Yield |
---|---|---|
2011 | $0.560 | 1.01% |
2012 | $1.440 | 2.25% |
2013 | $1.880 | 2.11% |
2014 | $2.44 | 2.11% |
2015 | $3.16 | 1.98% |
2016 | $4.00 | 2.53% |
2017 | $4.60 | 3.05% |
2018 | $5.28 | 2.98% |
2019 | $5.80 | 3.02% |
2020 | $6.40 | 2.67% |
2021 | $7.04 | 3.11% |
2022 | $7.76 | 3.42% |
2023 | $8.52 | 3.26% |
2024 | $2.25 | 0.76% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.238 | 1.500 | 5.23 | 7.85 | [0 - 0.5] |
returnOnAssetsTTM | 0.0691 | 1.200 | 7.70 | 9.23 | [0 - 0.3] |
returnOnEquityTTM | 1.033 | 1.500 | 10.00 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.678 | -1.000 | 3.22 | -3.22 | [0 - 1] |
currentRatioTTM | 1.649 | 0.800 | 6.75 | 5.40 | [1 - 3] |
quickRatioTTM | 1.622 | 0.800 | 5.17 | 4.13 | [0.8 - 2.5] |
cashRatioTTM | 0.595 | 1.500 | 7.81 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.665 | -1.500 | 10.00 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 3.15 | 1.000 | 9.94 | 9.94 | [3 - 30] |
operatingCashFlowPerShareTTM | 15.83 | 2.00 | 4.72 | 9.44 | [0 - 30] |
freeCashFlowPerShareTTM | 13.76 | 2.00 | 3.12 | 6.24 | [0 - 20] |
debtEquityRatioTTM | 10.37 | -1.500 | 10.00 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.700 | 1.000 | 1.663 | 1.663 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.321 | 1.000 | 5.57 | 5.57 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.131 | 1.000 | -0.383 | -0.383 | [0.2 - 2] |
assetTurnoverTTM | 0.290 | 0.800 | -1.399 | -1.119 | [0.5 - 2] |
Total Score | 10.02 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 21.50 | 1.000 | 7.93 | 0 | [1 - 100] |
returnOnEquityTTM | 1.033 | 2.50 | 3.34 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 13.76 | 2.00 | 5.41 | 6.24 | [0 - 30] |
dividendYielPercentageTTM | 3.20 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 15.83 | 2.00 | 4.72 | 9.44 | [0 - 30] |
payoutRatioTTM | 0.678 | 1.500 | 3.22 | -3.22 | [0 - 1] |
pegRatioTTM | 0.622 | 1.500 | 9.19 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.300 | 1.000 | 4.99 | 0 | [0.1 - 0.5] |
Total Score | 6.55 |
Amgen Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。